Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of ...

South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...

Korea's pharmaceutical giant Celltrion said Monday that it has received approval from Canadian health authorities for a ...

Discover five biosimilar companies creating affordable versions of blockbuster drugs and hoping to capitalize on the upcoming ...

The drugmaker will use the new facility as a pipeline for existing and new product manufacturing, including biosimilars ...

Biopharmaceutical company Celltrion said Thursday that it began the commercial operation of its third plant for drug ...

South Korean biopharmaceutical firm Celltrion announced Thursday that its third plant in Songdo, Incheon, has officially ...

South Korea’s biosimilar maker Celltrion Inc. on Wednesday announced a plan to retire about a quarter of its treasury stock ...